Sarah Scagliarini, Medical Oncologist at AORN Cardarelli in Naples, shared a post on X by ESMO, adding:
“Very interesting! In adj more than m cancer! But without data it will seem just a suggestion… so let’s all work together to improve PROs (different for each tumor/therapy as Cristiane Bergerot’s work) in all RCTs and investigate in RWE the differences with CROs!”
Quoting European Society for Medical Oncology (ESMO)’s post:
“Do clinicians and patients see the same picture? In adjuvant BC therapy trials, agreement on side effects is weak. Patient-reported outcomes (PROs) show symptoms that doctors often don’t see. Both views are vital for patient-centred care.”
Sarah Scagliarini responded to an ESMO post highlighting discrepancies between clinician and patient perspectives on side effects in adjuvant breast cancer therapy. She underscored the need for better integration of patient-reported outcomes (PROs) in randomized clinical trials and real-world evidence, referencing the work of Cristiane Bergerot as a model for tumor- and therapy-specific approaches.
More posts featuring ESMO.